Key facts
- Avicenna Biosciences’s last known valuation is $5.1M (Sep 2020).
- It has raised $20.5M across 4 recorded rounds; the latest was Seed Round ($3.0M) in Apr 2022.
- Notable investors include DCVC, DCVC Bio.
- Avicenna Biosciences has filed 6 Form Ds with the SEC since 2020, most recently Jul 2024 ($6.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Avicenna Biosciences
Funding rounds
4 roundsAbout Avicenna Biosciences
Developer of an ML-driven medicinal chemistry platform intended to redesign and optimize drug candidates. The company utilizes ensemble-based machine learning approaches to identify new chemical entities and expand the range of challenges that can be overcome, and transform sub-optimal development candidates into life-saving drugs, and make lead optimization faster and cheaper, enabling pharmaceutical companies to reduce any deficiencies in their drugs.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2020
- Employees
- 12
- Website
- avicenna-bio.com/
- Ownership
- Privately Held (backing)
Avicenna Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avicenna Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avicenna Biosciences in its N-PORT filings yet. We sweep new filings monthly.